Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fosun Pharma’s H1 Profit Leaps 144 Percent

This article was originally published in PharmAsia News

Executive Summary

Fosun Pharma has reported that its gross profit reached RMB 631 million while net profit attributable to shareholders of its parent company hit RMB 496 million in the first half of 2008, up 145 percent and 144 percent respectively over the same periods last year. The huge jump results from rapid expansion of its drug R&D, pharmaceutical business, and investment in high-performing Sinopharm Medicine Holding. Fosun's pharmaceutical R&D core enterprises such as Newsummit Biopharma, Chongqing Yaoyou Pharmaceuticals and Wanbang Biopharma all achieved impressive growth rates greatly exceeding the industry average. Fosun's key products - antimalarial drug Co-Artesun, insulin drug Glimepiride and liver-care drug Atuomolan - continue to maintain leading positions in their individual market segments. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts